Intelivation Technologies today announced the successful first clinical use of its Advantage-C™ Ti3D Cervical Interbody Device.

Valgen Medtech recently announced that its proprietary DragonFly™ Transcatheter Mitral Valve Repair System has received CE mark approval in the European Union for the treatment of Functional Mitral Regurgitation (FMR).

Dexcom has announced several developments aimed at expanding access to glucose biosensing technology, including FDA clearance for paediatric use of its Stelo Glucose Biosensor and the launch of a redesigned Stelo mobile application in the United States.

HistoSonics, developer of the Edison® Histotripsy System and histotripsy therapy platforms, has completed a new financing round with participation from Yosemite, led by Reed Jobs, along with several new strategic investors. Financial details of the investment were not disclosed.

MediThinQ, a South Korea-based developer of surgical visualisation technologies, has signed an exclusive multi-year distribution agreement with Synovis Micro Companies Alliance, Inc. (Synovis MCA),

WISE S.p.A., a medical device company focused on implantable electrodes for neuromonitoring, neuromodulation and brain-computer interface (BCI) applications, has completed an oversubscribed Series D financing round worth €30 million.

Oculogica has received US Food and Drug Administration (FDA) 510(k) clearance for its SNAP concussion test, a non-invasive diagnostic tool designed to assess concussion in just 90 seconds.

Penumbra, Inc. has received CE Mark approval in Europe for THUNDERBOLT, its computer assisted vacuum thrombectomy (CAVT) technology for the treatment of acute ischaemic stroke. The milestone follows recent clearance

Chiesi Group, a research-focused biopharmaceutical company, has completed its acquisition of KalVista Pharmaceuticals. KalVista will now operate as part of Chiesi’s Rare Diseases business unit

Wave Neuroscience, in collaboration with the Texas A&M Health Institute of Biosciences and Technology, has received clearance from the U.S. Food and Drug Administration (FDA) for its MeRT System for the treatment of Post-Traumatic Stress Disorder (PTSD).